# US 2018/0021365 A1 · Enhanced cancer treatment and monitoring using recombinant vectors

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2018/0021365 A1
- Document ID: US20180021365A1
- Status: Published application
- Kind: A1
- Application number: 15/611,722
- Filed: 2017-06-01
- Published: 2018-01-25
- Earliest claimed: 2010-10-31
- Assignees: Tocagen Inc.
- Applicants: Tocagen Inc.
- Inventors: Harry E. Gruber; Douglas J. Jolly; Derek G. Ostertag; Ryan S. Burnett; Amy H. Lin; Tiffany Huang; Joan M. Robbins
- Web page: https://patentgrep.com/patent/US20180021365A1

## CPC

- A61K 31/7088: Compounds having three or more nucleosides or nucleotides
- A61K 9/127: Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
- A61K 31/56: Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K 31/573: substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
- A61K 31/58: containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin (digitoxin {A61K31/7048})
- A61K 31/713: Double-stranded nucleic acids or oligonucleotides
- A61K 35/768: Oncolytic viruses not provided for in groups A61K35/761 - A61K35/766
- A61K 39/21: Retroviridae, e.g. equine infectious anemia virus
- A61K 39/3955: {against proteinaceous materials, e.g. enzymes, hormones, lymphokines}
- A61K 39/39558: {against tumor tissues, cells, antigens}
- A61N 5/10: X-ray therapy; Gamma-ray therapy; Particle-irradiation therapy (A61N5/01 takes precedence)
- A61P 35/00: Antineoplastic agents
- C12N 15/867: Retroviral vectors
- C12N 2740/13032: Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61N: ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY (measurement of bioelectric currents A61B; surgical instruments, devices or methods for transferring non-mechanical forms of energy to or from the body A61B18/00; anaesthetic apparatus in general A61M; incandescent lamps H01K; infrared radiators for heating H05B)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)

## Abstract

This disclosure relates to replication competent viral vectors for treating cell proliferative disorders. The disclosure further relates to the use of such replication competent viral vectors for delivery and expression of a heterologous nucleic acid in normal and diseased tissues and methods and compositions that facilitate such delivery and expression to tissues in vivo and in vitro. The disclosure further relates to replication competent retroviral vectors for these uses and in conjunction with methods and compositions that facilitate in vivo therapeutics.

## Claims

### Claim at position 1

1-18. (canceled)

### Claim 19

A method of treating a subject with a cancer, comprising:
administering to the subject a replicative viral vector comprising a polynucleotide encoding a polypeptide having cytosine deaminase activity;
administering 5-fluorocytosine (5-FC) to the subject, wherein the polypeptide converts 5-FC to 5-fluorouracil (5-FU); and
subjecting the subject to radiation therapy so as to cause death of cancer cells wherein the cancer cells are more sensitive to radiation therapy by having local concentrations of 5-FU.

### Claim 20 (depends on 19)

The method of claim 19, wherein an inhibitor of pattern recognition receptor (PRR) or interferon (IFN) signaling pathways is administered to the subject at the same time as the replicative viral vector is administered to the subject.

### Claim 21 (depends on 19)

The method of claim 19, wherein an inhibitor of PRR or IFN signaling pathways is administered to the subject within a period of one day before to 2 days after administration of the replicative viral vector to the subject.

### Claim 22 (depends on 21)

The method of claim 21, wherein the inhibitor of IFN signaling is an anti-IFN antibody or anti-IFN receptor antibody.

### Claim 23 (depends on 19)

The method of claim 19, wherein the replicative viral vector is a recombinant replicative retrovirus or a recombinant replicative retroviral vector.

### Claim 24 (depends on 23)

The method of claim 23, wherein one or more doses of the recombinant replicative retrovirus is administered locally at the site of the cancer.

### Claim 25 (depends on 23)

The method of claim 23, wherein one or more doses of the recombinant replicative retrovirus is administered intravenously.

### Claim 26 (depends on 25)

The method of claim 25, wherein each dose of the one or more doses of the recombinant replicative retrovirus comprises from 105 to 1012 transducing units (TU) of the recombinant replicative retrovirus.

### Claim 27 (depends on 23)

The method of claim 23, wherein the replication competent retrovirus comprises:
a retroviral GAG protein;
a retroviral POL protein;
a retroviral envelope;
a retroviral polynucleotide comprising Long-Terminal Repeat (LTR) sequences at the 3′ end of the retroviral polynucleotide sequence, a promoter sequence at the 5′ end of the retroviral polynucleotide, said promoter being suitable for expression in a mammalian cell, a gag nucleic acid domain, a pol nucleic acid domain and an env nucleic acid domain;
a cassette comprising an internal ribosome entry site (IRES) operably linked to a heterologous polynucleotide that encodes a polypeptide having cytosine deaminase activity, wherein the cassette is positioned 5′ to the 3′ LTR and 3′ to the env nucleic acid domain encoding the retroviral envelope; and
cis-acting sequences necessary for reverse transcription, packaging and integration into a neoplastic cell.

### Claim 28 (depends on 27)

The method of claim 27, wherein the retroviral polynucleotide sequence is derived from a murine leukemia virus (MLV), a Moloney murine leukemia virus (MoMLV), a Feline leukemia virus (FeLV), or a Gibbon ape leukemia virus (GALV).

### Claim 29 (depends on 27)

The method of claim 27, wherein the retroviral envelope is an amphotropic MLV envelope.

### Claim 30 (depends on 19)

The method of claim 19, wherein the polynucleotide comprises a cytosine deaminase sequence that has been human codon optimized and/or comprises mutations that increase the cytosine deaminase's stability compared to a wild-type cytosine deaminase.

### Claim 31 (depends on 19)

The method of claim 19, wherein 5-FC is administered 6 to 14 days after administering the replicative viral vector to the subject.

### Claim 32 (depends on 19)

The method of claim 19, wherein one or more doses of 5-FC are orally administered to the subject.

### Claim 33 (depends on 32)

The method of claim 32, wherein each dose of the one or more doses of 5-FC comprises up to 500 mg/kg of 5-FC.

### Claim 34 (depends on 19)

The method of claim 19, wherein the cancer is a brain cancer.

### Claim 35 (depends on 34)

The method of claim 34, wherein the brain cancer is glioblastoma multiforme.

### Claim 36 (depends on 19)

The method of claim 19, wherein the subject is subjected to radiation when α-fluoro-β-alanine (FBAL) levels are at a therapeutic level that causes increased radiosensitization by tumor cells that convert 5-FC to 5-FU.
